Jerry Avorn

Q: What Schools Are Affiliated With Jerry Avorn

Jerry Avorn is affiliated with the following schools: University of California, Los Angeles, University of Washington, Columbia University, Harvard University

Jerry Avorn's AcademicInfluence.com Rankings

Jerry Avorn

Philosophy

#2360

World Rank

#4059

Historical Rank

#855

USA Rank

Logic

#568

World Rank

#1026

Historical Rank

#221

USA Rank

philosophy Degrees

Download Badge

Philosophy

Jerry Avorn's Degrees

Doctorate Medicine Harvard University

Why Is Jerry Avorn Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jerry Avorn is a professor of medicine at Harvard Medical School and Chief Emeritus of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. He founded one of the largest programs using health care utilization data to track medication use and outcomes, and invented the practice of "academic detailing" in which pharmacists, nurses, and physicians educate doctors about cost-effective prescribing practices using the same tactics that drug companies employ to market their products. He received a B.A. from Columbia University in 1969 and M.D. from Harvard Medical School in 1974.

(See a Problem?)

Jerry Avorn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Variable selection for propensity score models. (2006) (1769)
Long-term persistence in use of statin therapy in elderly patients. (2002) (1229)
A review of uses of health care utilization databases for epidemiologic research on therapeutics. (2005) (1161)
Principles of educational outreach ('academic detailing') to improve clinical decision making. (1990) (1077)
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. (2005) (927)
High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data (2009) (926)
Improving Drug-Therapy Decisions through Educational Outreach (1983) (760)
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. (2004) (734)
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. (2001) (708)
A combined comorbidity score predicted mortality in elderly patients better than existing scores. (2011) (708)
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. (2006) (668)
Persistence of use of lipid-lowering medications: a cross-national study. (1998) (667)
Incidence and preventability of adverse drug events in nursing homes. (2000) (644)
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. (2003) (631)
Scientific versus commercial sources of influence on the prescribing behavior of physicians. (1982) (624)
Full coverage for preventive medications after myocardial infarction. (2011) (621)
Adherence to therapy with oral antineoplastic agents. (2002) (572)
Reduction of bacteriuria and pyuria after ingestion of cranberry juice. (1994) (564)
Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults (2004) (520)
The exclusion of the elderly and women from clinical trials in acute myocardial infarction. (1992) (518)
Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. (1991) (509)
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. (2004) (504)
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. (2016) (426)
Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. (2007) (424)
HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. (2000) (423)
Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". (1983) (423)
Improving drug prescribing in primary care: a critical analysis of the experimental literature. (1989) (412)
Risk factors for adverse drug events among nursing home residents. (2001) (399)
Patterns of cardiovascular risk in rheumatoid arthritis (2006) (397)
A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. (1992) (384)
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. (2006) (377)
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. (2007) (368)
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. (2010) (361)
The ambiguous relation between aging and adverse drug reactions. (1991) (333)
Compliance with osteoporosis medications. (2005) (313)
Glucocorticoids and the risk for initiation of hypoglycemic therapy. (1994) (310)
Payment Restrictions for Prescription Drugs under Medicaid (1987) (307)
Cultural and Economic Factors That (Mis)Shape Antibiotic Use: The Nonpharmacologic Basis of Therapeutics (2000) (306)
The implications of therapeutic complexity on adherence to cardiovascular medications. (2011) (301)
Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. (2003) (295)
The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. (1997) (292)
Noncompliance with congestive heart failure therapy in the elderly. (1994) (291)
Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. (2001) (288)
Treatment for glaucoma: adherence by the elderly. (1993) (284)
Improved comorbidity adjustment for predicting mortality in Medicare populations. (2003) (278)
Psychoactive medication use in intermediate-care facility residents. (1988) (275)
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study (2002) (275)
Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. (1996) (274)
Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. (2001) (271)
Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis (2007) (268)
Internet marketing of herbal products. (2003) (268)
Physician motivations for nonscientific drug prescribing. (1989) (257)
Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs (2004) (256)
Aging and the anticoagulant response to warfarin therapy. (1992) (250)
The Quality of Pharmacologic Care for Vulnerable Older Patients (2004) (246)
Eculizumab in Severe Shiga-Toxin-Associated HUS (2011) (244)
Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results (2007) (243)
The $2.6 billion pill--methodologic and policy considerations. (2015) (241)
Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study (2012) (239)
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. (2002) (233)
Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis (2006) (229)
Zolpidem Use and Hip Fractures in Older People (2001) (229)
Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome (2009) (228)
A propensity analysis of late versus early nephrologist referral and mortality on dialysis. (2003) (227)
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. (2002) (227)
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. (2005) (226)
Predictors of Uncontrolled Hypertension in Ambulatory Patients (2001) (224)
Acetaminophen toxicity in an urban county hospital. (1998) (219)
Increased Antidepressant Use in Patients Prescribed β-Blockers (1986) (219)
Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index (2018) (218)
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. (2014) (216)
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus (2015) (214)
Economic implications of evidence-based prescribing for hypertension: can better care cost less? (2004) (212)
Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. (2016) (210)
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. (2010) (209)
Identification of individuals with CKD from Medicare claims data: a validation study. (2005) (209)
Influence of clinical knowledge, organizational context, and practice style on transfusion decision making. Implications for practice change strategies. (1990) (208)
Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. (1994) (204)
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. (2011) (200)
Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. (1987) (199)
A controlled trial of educational outreach to improve blood transfusion practice. (1993) (198)
Medicaid data as a resource for epidemiologic studies: strengths and limitations. (1989) (198)
Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs (2010) (195)
Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials (2009) (193)
Dopamine antagonists and the development of breast cancer. (2002) (189)
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. (2006) (184)
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. (2008) (183)
Patient, Physician, and Payment Predictors of Statin Adherence (2010) (183)
Paradoxical Relations of Drug Treatment with Mortality in Older Persons (2001) (182)
Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. (2007) (182)
Economic and Policy Analysis of University-based Drug “Detailing (1986) (179)
Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. (1997) (177)
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. (2005) (176)
A randomized study of how physicians interpret research funding disclosures. (2012) (174)
Statins and congenital malformations: cohort study (2015) (171)
Noncompliance with antihypertensive medications (2002) (171)
Use of psychoactive medication and the quality of care in rest homes. Findings and policy implications of a statewide study. (1989) (170)
Resident Behavior and Staff Distress in the Nursing Home (1991) (168)
Comparing mortality of elderly patients on hemodialysis versus peritoneal dialysis: a propensity score approach. (2002) (164)
Benefit and cost analysis in geriatric care. Turning age discrimination into health policy. (1984) (164)
Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. (2014) (164)
In defense of pharmacoepidemiology--embracing the yin and yang of drug research. (2007) (162)
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. (2007) (162)
Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. (2016) (161)
Improving Medication Prescribing and Utilization in the Nursing Home (1990) (161)
Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly (2006) (159)
Physician Attitudes Concerning Warfarin for Stroke Prevention in Atrial Fibrillation: Results of a Survey of Long‐Term Care Practitioners (1997) (159)
Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation (2012) (158)
Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. (2002) (155)
Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) (1999) (154)
Relationship Between COX-2 Specific Inhibitors and Hypertension (2004) (153)
Trouble getting started: predictors of primary medication nonadherence. (2011) (151)
Electronic medication packaging devices and medication adherence: a systematic review. (2014) (151)
Nephrologist care and mortality in patients with chronic renal insufficiency. (2002) (151)
Bowel habit in relation to age and gender. Findings from the National Health Interview Survey and clinical implications. (1996) (150)
Induced Disability in Nursing Home Patients: A Controlled Trial (1982) (149)
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. (2006) (146)
Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. (2006) (146)
Underuse of osteoporosis medications in elderly patients with fractures. (2003) (144)
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. (2012) (142)
Drug Evaluation during the Covid-19 Pandemic. (2020) (142)
Quality Indicators for Appropriate Medication Use in Vulnerable Elders (2001) (141)
Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post–Myocardial Infarction Medicare Beneficiaries (2008) (140)
Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes (2014) (140)
National trends in antidepressant medication treatment among publicly insured pregnant women. (2013) (138)
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. (2006) (137)
Guided prescription of psychotropic medications for geriatric inpatients. (2005) (137)
The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration (2011) (137)
Principles of Pharmacology (2003) (136)
Quality Indicators for Medication Use in Vulnerable Elders (2007) (134)
FDA Approval and Regulation of Pharmaceuticals, 1983-2018. (2020) (134)
Behavior changes after notification of HIV infection. (1991) (134)
Reduction of incorrect antibiotic dosing through a structured educational order form. (1988) (131)
Educating patients about their medications: the potential and limitations of written drug information. (2007) (129)
Evaluating drugs after their approval for clinical use. (1993) (129)
At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. (2010) (129)
Drug Use in the Nursing Home (1996) (126)
Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. (1990) (126)
Assessment of education and computerized decision support interventions for improving transfusion practice (2007) (125)
Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing (2001) (125)
The costs and benefits of enhanced depression care to employers. (2006) (124)
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. (2006) (123)
Practical, legal, and ethical issues in expanded access to investigational drugs. (2015) (123)
Antidepressant use in pregnancy and the risk of cardiac defects. (2014) (122)
Nonoccupational risk factors for carpal tunnel syndrome (1999) (121)
Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction (2000) (119)
Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. (1984) (118)
Determinants of delayed nephrologist referral in patients with chronic kidney disease. (2001) (115)
Medication Safety: Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use: A Systematic Review (2007) (115)
Racial differences in screening for prostate cancer in the elderly. (2004) (115)
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. (2007) (114)
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. (2013) (113)
Systemic effects of medications used to treat glaucoma. (1990) (112)
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. (2004) (112)
Performance of propensity score calibration--a simulation study. (2007) (112)
Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review (2011) (111)
Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information: The Example of COX2 Inhibitors and Myocardial Infarction (2005) (111)
Predictors of Physician Prescribing Change in an Educational Experiment to Improve Medication Use (1987) (111)
Self-management Education Programs in Chronic Disease (2004) (110)
Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment. (1990) (110)
Uric acid lowering therapy: prescribing patterns in a large cohort of older adults (2007) (109)
Multivariate predictors of blood product use in cardiac surgery. (2003) (109)
Drug prescribing for the elderly. (1986) (108)
How well do patients report noncompliance with antihypertensive medications?: a comparison of self‐report versus filled prescriptions (2004) (107)
Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation (2009) (106)
Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. (2018) (105)
Preterm Birth and Antidepressant Medication Use during Pregnancy: A Systematic Review and Meta-Analysis (2014) (103)
Antihypertensive Drug Therapy and the Initiation of Treatment for Diabetes Mellitus (1993) (101)
Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. (2003) (101)
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. (2008) (101)
Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. (2000) (100)
Drug-review deadlines and safety problems. (2008) (99)
Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. (2012) (99)
Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. (2015) (98)
Prophylactic Use of Factor VIII: an Economic Evaluation (1998) (98)
Lipid levels and bone mineral density. (2005) (98)
Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. (2008) (97)
Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults (2010) (96)
Effects of Noncardiovascular Comorbidities on Antihypertensive Use in Elderly Hypertensives (2005) (95)
The Epidemiology of Prescriptions Abandoned at the Pharmacy (2010) (95)
The 21st Century Cures Act--Will It Take Us Back in Time? (2015) (94)
Late referral and modality choice in end-stage renal disease. (2001) (94)
Clinical decision-making in the evaluation and treatment of insomnia. (1990) (92)
Debate about funding comparative-effectiveness research. (2009) (90)
Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? (2003) (90)
Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. (2003) (90)
The variability and quality of medication container labels. (2007) (90)
Burden of Changes in Pill Appearance for Patients Receiving Generic Cardiovascular Medications After Myocardial Infarction (2014) (90)
Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov (2018) (88)
Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information (2007) (88)
Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. (2016) (88)
Use of Health Care Databases to Support Supplemental Indications of Approved Medications (2018) (87)
Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. (2005) (87)
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. (2007) (87)
Is There a Relationship Between Patient Beliefs or Communication About Generic Drugs and Medication Utilization? (2009) (86)
New "21st Century Cures" Legislation: Speed and Ease vs Science. (2017) (86)
Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review (2009) (85)
Consistency of performance ranking of comorbidity adjustment scores in canadian and U.S. utilization data (2004) (85)
'Bench to behavior': translating comparative effectiveness research into improved clinical practice. (2010) (84)
Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. (1987) (84)
Antibiotic Use in Children – A Cross‐National Analysis of 6 Countries (2017) (84)
Information and education as determinants of antibiotic use: report of Task Force 5. (1987) (83)
Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. (2005) (82)
Anticholinergic drug use and bowel function in nursing home patients. (1993) (82)
Sudden uncontrollable somnolence and medication use in Parkinson disease. (2005) (82)
Constipation: Assessment and Management in an Institutionalized Elderly Population (1994) (81)
Epidemiologic and Diagnostic Aspects of Bacteriuria: A Longitudinal Study in Older Women (1995) (81)
Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. (2001) (80)
Blood donation by the elderly. Clinical and policy considerations. (1987) (79)
Clozapine Use and Risk of Diabetes Mellitus (2002) (79)
Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation (2013) (78)
Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. (1995) (78)
Medications and falls. Causation, correlation, and prevention. (1996) (78)
Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma. (1998) (77)
Thiazide diuretics and the initiation of anti-gout therapy. (1997) (77)
A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. (2005) (77)
Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. (2000) (76)
A randomized controlled trial of mailed osteoporosis education to older adults (2006) (75)
Changing Surgical Antimicrobial Prophylaxis Practices Through Education Targeted at Senior Department Leaders (1990) (75)
Refilling and Switching of Antiepileptic Drugs and Seizure‐Related Events (2010) (75)
Patterns of bone mineral density testing: current guidelines, testing rates, and interventions. (2004) (74)
Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. (2014) (73)
The role of litigation in defining drug risks. (2007) (73)
Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey (2013) (73)
Comparative Safety of Antipsychotic Medications in Nursing Home Residents (2012) (72)
The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. (2015) (72)
Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. (2007) (72)
The effect of altitude on dosing and response to erythropoietin in ESRD. (2008) (70)
Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. (2003) (70)
Late nephrologist referral and access to renal transplantation1 (2002) (69)
Approval of a tuberculosis drug based on a paradoxical surrogate measure. (2013) (68)
Academic Detailing: "Marketing" the Best Evidence to Clinicians. (2017) (68)
Influence of Knowledge and Attitudes on the Quality of Physicians' Transfusion Practice (1993) (68)
Patient, Physician, Pharmacy, and Pharmacy Benefit Design Factors Related to Generic Medication Use (2007) (68)
Increased antidepressant use in patients prescribed beta-blockers. (1986) (67)
Design of Cluster-Randomized Trials of Quality Improvement Interventions Aimed at Medical Care Providers (2007) (67)
Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010. (2016) (67)
Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgery. (2003) (67)
Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations (2004) (66)
Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges (2012) (65)
Dangerous deception--hiding the evidence of adverse drug effects. (2006) (65)
Quality assurance for drug prescribing. (1990) (65)
A randomized trial of an education, and support program for HIV‐infected individuals (1995) (65)
Variability in length of hospitalization for stroke. The role of managed care in an elderly population. (1996) (64)
Balancing innovation, access, and profits--market exclusivity for biologics. (2009) (64)
Prescription opioid use among older adults with arthritis or low back pain. (2006) (64)
Paying for drug approvals--who's using whom? (2007) (63)
Improving drug use in elderly patients: getting to the next level. (2001) (63)
Physicians' Knowledge of Drug Costs for the Elderly (1994) (62)
The impact of reducing cardiovascular medication copayments on health spending and resource utilization. (2012) (61)
Antidepressant use and the risk of breast cancer: a non-association. (2001) (61)
The hepatotoxicity of antifungal medications in bone marrow transplant recipients. (2005) (61)
Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus. (1999) (60)
Correlates of regular laxative use by frail elderly persons. (1995) (60)
The Psychology of Clinical Decision Making - Implications for Medication Use. (2018) (59)
Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit (2004) (59)
The neglected medical history and therapeutic choices for abdominal pain. A nationwide study of 799 physicians and nurses. (1991) (58)
The economic impact of factor VIII inhibitors in patients with haemophilia (2004) (58)
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison (2013) (58)
Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. (2006) (57)
Including elderly people in clinical trials (1997) (57)
Pharmacogenetic Testing in the Clinical Management of Schizophrenia: A Decision-Analytic Model (2005) (57)
Improving choice of prescribed antibiotics through concurrent reminders in an educational order form. (1993) (56)
A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences (2006) (56)
Pygmalion in the Nursing Home The Effects of Caregiver Expectations on Patient Outcomes (1990) (56)
The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. (2011) (56)
Increased incidence of levodopa therapy following metoclopramide use. (1995) (55)
How do older persons define constipation? Implications for therapeutic management. (1997) (55)
Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study (2008) (55)
Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age. (2007) (54)
Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use (2007) (54)
Suboptimal Antidepressant Use in the Elderly (2005) (54)
Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending. (2006) (54)
Osteoporosis Improvement: A Large‐Scale Randomized Controlled Trial of Patient and Primary Care Physician Education (2007) (53)
Risk Factors for Non‐Insulin‐Dependent Diabetes Mellitus Requiring Treatment in the Elderly (1994) (53)
Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. (2005) (53)
Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey (2016) (52)
Predialysis Nephrologist Care and Access to Kidney Transplantation in the United States (2007) (52)
The impact of sedative‐hypnotic use on sleep symptoms in elderly nursing home residents (1996) (51)
Sociodemographic and behavioral characteristics of HIV antibody-positive blood donors. (1988) (51)
Multivariate‐adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases (2010) (51)
Hetastarch and bleeding complications after coronary artery surgery. (2003) (51)
New FDA breakthrough-drug category--implications for patients. (2014) (51)
Statin lipid‐lowering drugs and bone mineral density (2005) (51)
Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. (2008) (50)
Defining “Innovativeness” in Drug Development: A Systematic Review (2013) (49)
Undertreatment of hypercholesterolaemia: a population-based study. (2003) (49)
Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings. (2012) (49)
Perceived health, life satisfaction, and activity in urban elderly: a controlled study of the impact of part-time work. (1983) (48)
Patterns of bone mineral density testing (2004) (47)
Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. (2014) (47)
Five features of value-based insurance design plans were associated with higher rates of medication adherence. (2014) (47)
The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs (2012) (47)
Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. (1999) (46)
Medication use in older patients: better policy could encourage better practice. (2010) (46)
Association of marketing interactions with medical trainees' knowledge about evidence-based prescribing: results from a national survey. (2014) (46)
Guidelines for Good Epidemiology Practices for Drug, Device, and Vaccine Research in the United States (1996) (46)
Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014. (2015) (45)
The most transformative drugs of the past 25 years: a survey of physicians (2013) (45)
The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. (2017) (45)
A cross-national study of the persistence of antihypertensive medication use in the elderly (2008) (44)
The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. (2003) (44)
The consequences of requesting "dispense as written". (2011) (44)
Trends in medication choices for hypertension in the elderly. The decline of the thiazides. (1995) (44)
Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. (1994) (44)
Comparative effectiveness of generic versus brand-name antiepileptic medications (2015) (43)
Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019) (42)
The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. (2011) (42)
Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents (2018) (42)
Epidemiology of Adverse Drug Events in the Nursing Home Setting (1995) (42)
False Claims Act prosecution did not deter off-label drug use in the case of neurontin. (2011) (42)
Progress and Hurdles for Follow-on Biologics. (2015) (41)
Overmedication of the low-weight elderly. (1987) (41)
Comparative mortality risk of anemia management practices in incident hemodialysis patients. (2010) (41)
Medication use and the elderly: current status and opportunities. (1995) (41)
Osteoporosis medication use in nursing home patients with fractures in 1 US state. (2008) (41)
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. (2007) (41)
Finding Incident Breast Cancer Cases through US Claims Data and a State Cancer Registry (2001) (40)
FDA standards--good enough for government work? (2005) (40)
Definition of Race and Ethnicity in Older People in Medicare and Medicaid (1999) (39)
Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. (2007) (39)
Putting adverse drug events into perspective. (1997) (39)
Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures (2012) (39)
The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness. (2011) (39)
Learning about the safety of drugs--a half-century of evolution. (2011) (39)
Health Education about AIDS among Seropositive Blood Donors (1986) (39)
Managing drug-risk information--what to do with all those new numbers. (2009) (38)
A substantial cause of preventable illness (2008) (38)
The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. (1996) (38)
Two centuries of assessing drug risks. (2012) (37)
Cimetidine Use in Nursing Homes: Prolonged Therapy and Excessive Doses (1987) (37)
The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. (2003) (37)
Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. (2012) (37)
Depressive symptoms in blood donors notified of HIV infection. (1993) (36)
Teaching clinicians about drugs--50 years later, whose job is it? (2011) (36)
Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. (2006) (36)
Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. (2004) (36)
Comparing the Costs, Risks, and Benefits of Competing Strategies for the Primary Prevention of Venous Thromboembolism (2004) (36)
Pharmacological Management of Osteoporosis in Nursing Home Populations: A Systematic Review (2009) (35)
Older adults' knowledge and beliefs about osteoporosis: results of semistructured interviews used for the development of educational materials. (2005) (35)
Evaluating drug effects in the post-Vioxx world: there must be a better way. (2006) (35)
Determinants of Market Exclusivity for Prescription Drugs in the United States (2017) (35)
Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications? An Evaluation of the Target Pharmacy Label (2009) (35)
Kidney function and use of recommended medications after myocardial infarction in elderly patients. (2006) (34)
Trends in Knee Magnetic Resonance Imaging (2003) (34)
The Appropriateness of Oral Fluoroquinolone‐Prescribing in the Long‐Term Care Setting (1994) (33)
Torcetrapib and atorvastatin--should marketing drive the research agenda? (2005) (33)
A model for improving medication use in home health care patients. (1998) (33)
State Initiatives to Control Medication Costs--Can Transparency Legislation Help? (2016) (32)
Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications (2015) (32)
Pharmaceutical promotion to physicians and First Amendment rights. (2008) (32)
Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments (2012) (32)
University-based science and biotechnology products: defining the boundaries of intellectual property. (2005) (32)
Strategies That Delay Market Entry of Generic Drugs (2017) (31)
Conflict of interest in oncology publications (2012) (31)
Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. (2010) (31)
The FDA Breakthrough-Drug Designation - Four Years of Experience. (2018) (31)
Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism (2000) (31)
Antipsychotic agents and sudden cardiac death--how should we manage the risk? (2009) (30)
Keeping science on top in drug evaluation. (2007) (30)
How Do Older Persons Define Constipation? (2006) (30)
Hemophilia Home Treatment: Economic Analysis and Implications for Health Policy (1995) (30)
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. (2012) (30)
A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial (2009) (30)
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high‐titre inhibitors (2005) (30)
The economic consequences of non-evidence-based clopidogrel use. (2008) (29)
Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. (2010) (29)
Drug warnings that can cause fits--communicating risks in a data-poor environment. (2008) (29)
Educational Outreach to Opioid Prescribers: The Case for Academic Detailing. (2017) (29)
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem‐containing medications (2017) (28)
Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. (2016) (28)
Coxibs, science, and the public trust. (2005) (28)
Persistent Opioid Use Following Cesarean Delivery: Patterns and Predictors Among Opioid-naive Women (2017) (28)
Advertising and prescription drugs: promotion, education, and the public's health. (2003) (28)
Mandatory disclaimers on dietary supplements do not reliably communicate the intended issues. (2015) (28)
Origins of Medical Innovation: The Case of Coronary Artery Stents (2012) (27)
Changing prescribing practices through individual continuing education. (1987) (27)
Adverse Pulmonary Effects of Topical β Blockers Used in the Treatment of Glaucoma (1993) (27)
Trends in Insulin Initiation and Treatment Intensification Among Patients with Type 2 Diabetes (2014) (27)
Funding for medical education: maintaining a healthy separation from industry. (2010) (26)
Patients’ Preferences in Anticoagulant Therapy: Discrete Choice Experiment (2014) (26)
The elderly and drug policy: coming of age. (1990) (26)
Biomedical patents and the public's health: is there a role for eminent domain? (2006) (26)
Policy analysis of the conversion of histamine2 antagonists to over-the-counter use. (1997) (25)
Highlights and a hidden hazard--the FDA's new labeling regulations. (2006) (25)
New FDA breakthrough-drug category--implications for patients. (2014) (25)
Cardiovascular responses to phlebotomy and sitting in middle-aged and elderly subjects. (1992) (25)
FDA Regulation and Approval of Medical Devices: 1976-2020. (2021) (25)
Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs (2013) (25)
Long-Term Cost-Effectiveness of Providing Full Coverage for Preventive Medications After Myocardial Infarction (2015) (24)
Medication adherence and healthcare disparities: impact of statin co-payment reduction. (2015) (24)
Propensity score calibration in the absence of surrogacy. (2012) (24)
Depression in the elderly--falls and pitfalls. (1998) (24)
An Evaluation of the Relationship Between the Implementation of a Newly Designed Prescription Drug Label at Target Pharmacies and Health Outcomes (2009) (23)
Which Patients are Treated for Glaucoma? An Observational Analysis (2000) (23)
Reporting drug side effects: signals and noise. (1990) (23)
Part "D" for "defective"--the Medicare drug-benefit chaos. (2006) (23)
The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 (2006) (23)
The impact of cost sharing on antidepressant use among older adults in British Columbia. (2008) (23)
The appropriateness of oral fluoroquinolone prescribing in the long-term care setting (1995) (23)
Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model. (2004) (23)
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction (1995) (23)
The Prescription as Final Common Pathway (1995) (23)
Pharmaceutical cost containment with reference-based pricing: time for refinements. (2002) (22)
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study (2017) (22)
Preventive health care measures before and after start of renal replacement therapy (2002) (22)
Effect of hospitalwide change in clindamycin dosing schedule on clinical outcome. (1989) (22)
Using a drug-safety tool to prevent competition. (2014) (22)
Medicaid prescription limits: policy trends and comparative impact on utilization (2015) (22)
Old age and race as determinants of initiation of glaucoma therapy. (1993) (22)
Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. (2017) (21)
Failure of evidence-based medicine in the treatment of hypertension in older patients (2000) (21)
COX‐2 selective non‐steroidal anti‐inflammatory drugs and cardiovascular disease (2003) (21)
Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VI (2017) (21)
Transforming trial results into practice change: the final translational hurdle: Comment on "Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use". (2010) (21)
Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency. (2020) (21)
Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis (2018) (21)
Over-the-Counter Statins (2005) (20)
An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19. (2020) (20)
A new approach to reducing suboptimal drug use. (1983) (20)
Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects. (2000) (20)
Topical glaucoma medications and cardiovascular risk in the elderly (1994) (19)
Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia (2012) (19)
Risk of Ischemic Cerebrovascular and Coronary Events in Adult Users of Anticonvulsant Medications in Routine Care Settings (2013) (19)
Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease (2002) (19)
Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction. (2004) (19)
Urinary Antispasmodic Use and the Risks of Ventricular Arrhythmia and Sudden Death in Older Patients (2002) (18)
The effect of altitude change on anemia treatment response in hemodialysis patients. (2011) (18)
Making the Case for Accelerated Withdrawal of Aducanumab. (2022) (17)
Patterns of drug use in rheumatoid arthritis. (2000) (17)
Osteoporosis action: design of the healthy bones project trial. (2005) (17)
Application and impact of run-in studies (2018) (17)
Forbidden and Permitted Statements about Medications--Loosening the Rules. (2015) (17)
Up Against the Ivy Wall: a History of the Columbia crisis (1968) (16)
The Impact of Cost Sharing on Antidepressant Use Among Older Adults in British Columbia (2008) (16)
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs. (2014) (16)
The rise and fall of Natrecor for congestive heart failure: implications for drug policy. (2006) (16)
Do the research goal and databases match? A checklist for a systematic approach. (2001) (16)
Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study. (2015) (16)
Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. (2002) (16)
Communicating Drug Benefits and Risks Effectively: There Must Be a Better Way (2009) (16)
Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. (2010) (15)
Quantifying The Food And Drug Administration's rulemaking delays highlights the need for transparency. (2014) (15)
Biomedical and Social Determinants of Cognitive Impairment in the Elderly (1983) (15)
Old age--is it a risk for adverse drug reactions? (1990) (15)
Comparison of the Impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management Trial on Prescribing Patterns: A Time-Series Analysis (2008) (15)
Gastrointestinal complications of nonsteroidal antiinflammatory drugs: prophylactic and therapeutic strategies. (1995) (15)
Assessing Health State Utilities in Elderly Patients at Cardiovascular Risk (2006) (15)
Relationship between long bone fractures and water fluoridation. (1986) (14)
Antipsychotic Prescribing Patterns and the Treatment of Extrapyramidal Symptoms in Older People (1995) (14)
Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States (2015) (14)
Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study (2007) (14)
Methylergonovine maleate and the risk of myocardial ischemia and infarction. (2013) (14)
Warnings Without Guidance: Patient Responses to an FDA Warning About Ezetimibe (2012) (14)
Angiotensin inhibition after myocardial infarction: Does drug class matter? (2006) (14)
Patent Law and Policy (2007) (14)
Association of Medical Students' Reports of Interactions with the Pharmaceutical and Medical Device Industries and Medical School Policies and Characteristics: A Cross-Sectional Study (2014) (14)
Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation:A Population-Based Cohort Study. (2020) (14)
Postmarketing studies of drug safety (2011) (14)
Regulation of devices (2010) (14)
Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval. (2020) (13)
Balancing the cost and value of medications: the dilemma facing clinicians. (2002) (13)
Re‐using Mini‐Sentinel data following rapid assessments of potential safety signals via modular analytic programs (2013) (13)
The Impact of Thiazide Diuretics on the Initiation of Lipid‐Reducing Agents in Older People: A Population‐Based Analysis (1997) (13)
Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA (2013) (13)
The effect of cranberry juice on the presence of bacteria and white blood cells in the urine of elderly women. What is the role of bacterial adhesion? (1996) (13)
Clinicians’ Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation (2014) (13)
FDA regulation of off-label drug promotion under attack. (2013) (13)
Medical Schools' Industry Interaction Policies Not Associated With Trainees' Self-Reported Behavior as Residents: Results of a National Survey. (2015) (12)
Methylergonovine Maleate and the Risk of Myocardial Ischemia and Infarction (2014) (12)
Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem (2019) (12)
Correlations of nursing home characteristics with prescription of osteoporosis medications. (2011) (12)
Cost-effectiveness--can it be measured? (1993) (12)
Which patients with knee problems are likely to benefit from nonarthroplasty surgery? Development of a clinical prediction rule. (2004) (12)
US Taxpayers Heavily Funded the Discovery of COVID‐19 Vaccines (2021) (12)
Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples (2012) (12)
Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting (2000) (11)
Epidemiology in Plato's cave: claims data and clinical reality. (1991) (11)
The NIH translational research center might trade public risk for private reward (2011) (11)
An Algorithmic Computerised Order Entry Approach to Assist in the Prescribing of New Therapeutic Agents (2004) (11)
NSAID switching and short‐term gastrointestinal outcome rates after the withdrawal of rofecoxib (2009) (10)
Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients. (2007) (10)
Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey (2019) (10)
The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later. (2018) (10)
Benefit and Cost Analysis in Geriatric Care: Turning Age Discrimination into Health Policy (1985) (10)
Are Risk Evaluation and Mitigation Strategies Associated With Less Off‐Label Use of Medications? The Case of Immune Thrombocytopenia (2015) (10)
Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. (2002) (10)
The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness research. (2012) (10)
New and unproved medical devices (2013) (10)
Pharmacoepidemiology and rheumatic diseases: 2001–2002 (2003) (10)
Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval (2016) (10)
Nursing-home infections - the context. (1981) (10)
Practice-based outcomes research: crucial, feasible, and neglected. (1996) (10)
The Price of Crossing the Border for Medications. (2017) (9)
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors (2017) (9)
Propensity Score Calibration and its Alternatives. (2007) (9)
Drug regulation and drug information--who should do what to whom? (1995) (9)
Propranolol and the risk of hospitalized myopathy: translating chemical genomics findings into population-level hypotheses. (2010) (9)
Death from irreversible pulmonary hypertension associated with short-term use of fenfluramine and phentermine. (1997) (9)
An examination of the relationship between long bone fractures and community water fluoridation in an elderly female medicaid population (1986) (9)
Coagulation and adulteration--building on science and policy lessons from 1905. (2008) (9)
Using Patent Data to Assess the Value of Pharmaceutical Innovation (2009) (9)
The Medical License Number Accurately Identifies the Prescribing Physician in a Large Pharmacy Claims Database (2007) (9)
Stürmer et al. Respond to "Propensity Score Methods in Epidemiology" (2007) (9)
Medicine, health, and the geriatric transformation. (1986) (9)
Attitudes of the medical profession toward drug abuse. (1973) (8)
Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease. (2012) (8)
What is the public's right to access medical discoveries based on federally funded research? (2014) (8)
The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation (2012) (8)
Step Therapy-Clinical Algorithms, Legislation, and Optimal Prescribing. (2017) (8)
Going to see the doctor: The consultation process in general practice: by Gerry Stimson and Barbara Webb. Routledge and Kegan Paul, London, 1975. 155 pp (1978) (8)
Statins and the risk of colorectal cancer. (2005) (8)
Use of computer-based medicaid drug data to analyze and correct inappropriate medication use (1982) (8)
Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation? (2020) (8)
A Hemorrhage of Off-Label Use (2011) (8)
Life cycle of medical product rules issued by the US Food and Drug Administration. (2014) (8)
Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris. (2003) (8)
Public funding for transformative drugs: the case of sofosbuvir (2020) (8)
Pharmacology and geriatric practice: A case study in technology nontransfer (1987) (7)
Unhealthy ageing: functional and socioeconomic impact. (2001) (7)
Who is now responsible for discovering and warning about adverse effects of generic drugs? (2013) (7)
Drug policy in the aging society. (1983) (7)
Trends in direct-to-consumer advertising of prescription contraceptives. (2015) (7)
Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. (2009) (7)
Paying for Prescription Drugs in the New Administration. (2021) (7)
Trends in sociodemographic and behavioral characteristics of HIV antibody-positive blood donors. (1991) (7)
The promise of pharmacoepidemiology in helping clinicians assess drug risk. (2013) (7)
Unintended Consequences of a Medicaid Prescription Copayment Policy (2014) (7)
Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers. (2019) (7)
Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma. (2022) (6)
High-Risk Patients' Readiness to Undergo BMD Testing for Osteoporosis Diagnosis in Pennsylvania (2009) (6)
Quality of Health Care Received by Older Adults (2004) (6)
The 21st Century Cures Act. (2015) (6)
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. (2018) (6)
Pre-randomization decisions and group stratification in a randomized controlled trial to improve prescribing (2004) (6)
New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence (2022) (6)
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. (2017) (6)
Longitudinal Trends and Variation in Antipsychotic Use in Older Adults After Cardiac Surgery (2018) (6)
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. (2002) (6)
Drug expenditures for hypertension: an empirical test of an economic model in a French population. (1997) (6)
Porcine factor VIII: pharmacoeconomics of inhibitor therapy (2002) (6)
Post-modern drug evaluation. The deconstruction of evidence-based regulation. (2000) (6)
General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment (2018) (6)
The Future of Drug-Pricing Transparency. (2021) (6)
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs (2021) (5)
RESPONSE: Re: Adherence to Therapy With Oral Antineoplastic Agents (2002) (5)
Computer-assisted drug data collection (1992) (5)
Prior Authorization Policies for Selective Cyclooxygenase-2 Inhibitors in Medicaid: A Policy Review (2006) (5)
Sending Pharma Better Signals (2005) (5)
Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors (2017) (5)
Risk, responsibility, and generic drugs. (2012) (5)
Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary. (2019) (5)
Pharmacoepidemiology and "in silico" drug evaluation: is there common ground? (2008) (5)
Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020 (2022) (5)
Concurrent use of antiulcerative agents. (1997) (5)
Improving the Quality and Cost—Effectiveness of Prescribing (2012) (5)
Panel III. Intervention: The use of drug utilization review outcomes * (1991) (5)
Recent developments in psychopharmacoepidemiology (2003) (4)
Engaging With Patients on Health Policy Changes: An Urgent Issue. (2018) (4)
Ethics and experts. 2. A physician's perspective. (1982) (4)
Drug Review Deadlines and Subsequent Safety Problems (2008) (4)
Improving the Quality of Health Care for Older Adults (2008) (4)
A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights. (2022) (4)
Applying Academic Detailing and Process Change to Promote Choosing Wisely. (2017) (4)
Medicaid-based pharmacoepidemiology: claims and counterclaims. (1990) (4)
The Potential Return on Public Investment in Detecting Adverse Drug Effects (2017) (4)
Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration (2022) (4)
Comparison of Performanceof Propensity Score Calibration and Multiple Imputation to Control for Unmeasured Confounding Using an Internal Validation Study (2006) (4)
Physician Perceptions of Step Therapy Prescribing Requirements. (2019) (4)
FDA Approval of Eteplirsen for Muscular Dystrophy-Reply. (2017) (3)
Bringing epidemiology into drug utilisation research (2003) (3)
Observational Studies of Drug Safety — Aprotinin and the Absence of Transparency (2006) (3)
Needs, Wants, Demands, and Interests (1983) (3)
Institutionalizing Misinformation - The Dietary Supplement Listing Act of 2022. (2022) (3)
Studying Cognitive Performance in the Elderly (1982) (3)
Patterns of glaucoma medication use in the elderly: 1980-1990. (1994) (3)
Antidepressant use in pregnancy and the risk of cardiac defects. (2014) (3)
Public-sector Contributions to Novel Biologic Drugs. (2021) (3)
Drug innovation and public policy: some speculations. (1986) (3)
Clinical Trials of Orphan Drugs for Cancer—Reply (2011) (3)
Post-Modern Drug Evaluation (2012) (3)
Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety (2018) (3)
Immunosuppressants, mortality, and risk of cancer (2009) (3)
Correction: cost-effectiveness of statins in older patients with myocardial infarction. (2002) (3)
Medication Use and the Elderly (1994) (3)
Using computer-based decision support to close the "know do" gap in lipid-lowering therapy. (2008) (3)
Review: good adherence (compared with poor adherence) to drug therapy is associated with a reduction in mortality. (2006) (2)
Holding Pharmaceutical and Medical Device Executives Accountable as Responsible Corporate Officers. (2022) (2)
Use and Abuse of Drugs in Older Persons (1999) (2)
Erratum to: Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey (2013) (2)
Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review. (2022) (2)
Healthcare and the Tooth Fairy (2012) (2)
Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study (2020) (2)
Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016 (2017) (2)
Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020 (2021) (2)
Patient Versus General Population Preferences In Anticoagulant Therapy (2015) (2)
Reimbursement for hemophilia care in the United States : current policies and future considerations (1994) (2)
The Price of Crossing the Border for Medications. (2017) (2)
298: Performance of Propensity Score Calibration (PSC) (2005) (2)
Physician Trainees’ Interactions with the Pharmaceutical Industry (2013) (2)
Erratum: Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy in older patients with myocardial infarction (Annals of Internal Medicine (2000) 132 (780-787)) (2002) (2)
REVIEW Adherence to Therapy With Oral Antineoplastic Agents (2002) (2)
Burden of Changes in Generic Pill Appearance (2014) (2)
COPD EXACERBATIONS AND PNEUMONIA HOSPITALIZATIONS IN NEW USERS OF COMBINATION MAINTENANCE INHALERS: A COMPARATIVE EFFECTIVENESS AND SAFETY STUDY (2021) (1)
Drug Labels: A Flawed Source of Data for Studying Orphan Drug Approvals (2012) (1)
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated. (2023) (1)
Improving drug utilization in primary care practice (1982) (1)
Biotechnology Products and University-Based Science—Reply (2005) (1)
Comment: Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies (2012) (1)
Prescription Refill Management and Its Effect on Adherence (2017) (1)
Treatment for glaucoma: Adherence by older persons in managed care (1996) (1)
Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards. (2021) (1)
Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization (2021) (1)
Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021. (2023) (1)
The Role of Pharmacoepidemiology in the Health‐Care System and Academia (2019) (1)
Reviewers for the Journal, January-June 2016. (2016) (1)
Healthcare and the tooth fairy. A merger that won't result in 'smarter' medicine. (1998) (1)
JAMA Peer Reviewers in 2018. (2019) (1)
Characteristics of Clinical Trials Launched Early in the COVID-19 Pandemic in the US and in France (2021) (1)
Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016. (2022) (1)
Trouble Getting Started: Predictors of Primary Medication (2011) (1)
Response to “Following the Money in Epilepsy Therapeutics” (2010) (1)
Factors Influencing Prescription Drug Costs in the United States-Reply. (2016) (1)
Variations in Generic Combination Opioid Use Across State Medicaid Programs (2020) (1)
The marketplace can't give us the drug safety data we need. (2007) (1)
Economic consequences of routine coronary angiography in low-risk patients with unstable angina (2002) (1)
Physician education and cost containment. (1985) (1)
Gerios: Recommending Drugs and Dosing for Elderly Patients (2002) (1)
Notification of aniti-HTLV-III positive blood donors: Psychosocial counseling and care issues (1987) (1)
Erratum to: Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications (2015) (1)
US public investment in development of mRNA covid-19 vaccines: retrospective cohort study (2023) (1)
JAMA Peer Reviewers in 2020. (2021) (1)
Bias in Comparative Effectiveness Studies Due to Regional Variation in Medical Practice Intensity: A Legitimate Concern, or Much Ado About Nothing? (2012) (1)
Balancing the Cost and Value of Medications (2012) (1)
Origins and Ownership of Remdesivir: Implications for Pricing (2020) (1)
Do gastroprotective drugs prevent NSAID toxicity? (2003) (1)
Views from Academia, Industry, Regulatory Agencies, and the Legal System (2013) (1)
Osteoporosis Telephonic Intervention to Improve Medication Adherence (OPTIMA): A Large Pragmatic Randomized Controlled Trial (2014) (1)
Report of Task Force 5 (1987) (1)
Heart Failure and Noncompliance in the Elderly-Reply (1994) (1)
CV1 NONCOMPLIANCE WITH STATIN THERAPY: LOST CLINICAL BENEFITS AND IMPLICATIONS FOR COST-EFFECTIVENESS (2002) (1)
Risk of myocardial infarction associated with selective COX-2 inhibitors: Questions remain. Authors' replies (2002) (1)
CN7: REDUCING ANTICHOLINERGIC ANTIDEPRESSANT USE IN THE ELDERLY: A RANDOMIZED TRIAL OF GROUP VERSUS INDIVIDUAL “ACADEMIC DETAILING” (1999) (1)
Pharmacy's wake-up call (2004) (1)
Equity in the receipt of oseltamivir in the United States during the H1N1 pandemic. (2014) (1)
In Opposition to Liberty: We Need a Sovereign to Govern Drug Claims (2015) (1)
Drug-Induced Constipation-Reply (1994) (1)
University in revolt: A history of the Columbia crisis, (1969) (1)
Comment on: Adherence to therapy with oral antineoplastic agents. Authors' reply (2002) (1)
Balancing Costs, Efficacy, and Side Effects (2012) (1)
Documenting, Understanding, and Fixing Psychoactive Drug Use in the Nursing Home (1992) (1)
KD-Tree Algorithm for Propensity Score Matching With Three or More Treatment Groups (2012) (1)
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices. (2023) (1)
Does adherence to medical therapy improve long-term survival after myocardial infarction? (2007) (0)
Error in Text. (2017) (0)
Does antipsychotic use increase risk of death among the elderly? Commentary (2006) (0)
Rethinking the Use of Physicians as Hired Expert Lecturers (2015) (0)
Drugs in the Institutionalized Elderly-Reply (1989) (0)
Health Affairs From The Clinical Trial Literature Designing Comparative Effectiveness Research On Prescription Drugs : Lessons (2010) (0)
Statins and congenital malformations: cohort study this access benefits you. Your matters (2015) (0)
The Prescribing Practices of Physicians (1986) (0)
Clinical and Policy Considerations (2016) (0)
Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients (2022) (0)
PROCEEDINGS OF THE DUTCH SOCIETY FOR CLINICAL PHARMACOLOGY AND BIOPHARMACY (2000) (0)
Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic (2021) (0)
P2.63: Controlling Confounding Using Propensity Scores: Increasing Use and Persisting Questions (2004) (0)
Rethinking the Use of Physicians as Hired Expert Lecturers (2014) (0)
FRAILTY AND COMPARATIVE EFFECTIVENESS AND SAFETY OF DABIGATRAN VS WARFARIN IN OLDER ADULTS WITH ATRIAL FIBRILLATION (2018) (0)
The Price of Crossing the Border for Medications. (2017) (0)
Antidepressant Use in Patients Prescribed β-Blockers-Reply (1986) (0)
Cranberry juice and prevention of recurrent urinary tract infection (1999) (0)
Evidence-based educational outreach to clinicians to counter pharmaceutical marketing (“academic detailing”) (2013) (0)
Thanks to Reviewers—2020 (2020) (0)
Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain—Reply (2002) (0)
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK x (2003) (0)
JAMA Peer Reviewers in 2004 (2016) (0)
Findings From the National Health Interview Survey and Clinical Implications (2017) (0)
Thanks to Reviewers2002 (2002) (0)
Drug Use in Academic Medical Centres in an Era of Ferment (2012) (0)
Inaccurate Reporting of Insulin Reimbursement-Reply. (2016) (0)
Warfarin in the frail elderly with atrial fibrillation: Results of a physician survey (1996) (0)
P95Trends in direct-to-consumer advertising for prescription contraceptives (2015) (0)
The Role of Pharmacoepidemiology in the Healthcare System and Academia (2019) (0)
VALIDATION OF A CLAIMS-BASED FRAILTY INDEX AGAINST PHYSICAL PERFORMANCE AND CLINICAL OUTCOMES (2018) (0)
Off-Label Drug Use: The Authors Reply (2012) (0)
EVIDENCE-BASED POLICY AND PRACTICE: PROSPECTS AND PERILS (2006) (0)
Industry Funding for Medical Education: Maintaining a Healthy Separation From (2010) (0)
Letters to the editor (2007) (0)
Prescribing decision making by medical residents on night shifts: A qualitative study (2022) (0)
The Pursuit of Happiness: Management of Depression in the Elderly A review for the practicing physician (2008) (0)
Jerry Avorn Effectiveness The Relative Cost-Effectiveness of Anticoagulants : Obvious , Except for the Cost and the (2011) (0)
Every clinician deserves an un-sales rep. (2007) (0)
Value-Based Insurance Design Cut Copayments And Increased (2010) (0)
Rates Of Medication Adherence Five Features Of Value-Based Insurance Design Plans Were Associated With Higher Shrank (2014) (0)
Generic Vs. Brand-name Fluticasone-Salmeterol in the Prevention of COPD Exacerbations (2023) (0)
Prescription Drugs : Promotion , Education , And The Public ’ s Health The proliferation of medical advertising is a symptom of the nation ’ s all-against-all vision of medicine as just another commodity (2003) (0)
Antiepileptic Medications and the Risk of Suicide—Reply (2010) (0)
Herstarten van antihypertensiva (2007) (0)
DRUG-INDUCED CONSTIPATION. AUTHORS' REPLY (1994) (0)
Drug revolution places prescribing practices in question. (1984) (0)
Advancing Science in the Service of Humanity Professionalism and Ethical Safeguards (2016) (0)
Nonadherence t o A djuvant T amoxifen T herapy i n W omen W ith Primary B reast C ancer (2003) (0)
HP2 IS IT COST-EFFECTIVE TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY? (2002) (0)
Surrogate Measures of Drug Efficacy-A Finger Pointing at the Moon. (2023) (0)
Osteoporosis action: design of the healthy bones project trial (2004) (0)
3 Comparison of the Incidence Rates of Thromboembolic Events Reported for Patients Prescribed Celecoxib and Meloxicam in General Practice in England Using Prescription-Event Monitoring (PEM) Data (174) (2003) (0)
Prescribing quality indicators in research and practice (2007) (0)
Doctors should pay greater attention to managing the risk-benefit relationship to improve care of patients over 65 , urge (0)
Reducing Co-Payments of Essential Cardiovascular Medications (2009) (0)
Q017: Predictors of medication compliance in a large population of hypertensive patients (1998) (0)
PCV24: BEYOND THE FIRST YEAR: PATTERNS AND PREDICTORS OF LONG-TERM STATIN UTILIZATION (2001) (0)
RE: Drug risk assessment and data reuse (2014) (0)
Over-the-Counter Availability of Rescue Inhalers for Asthma-Reply. (2022) (0)
Editorial comment on The Papworth bleeding risk score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early post-operative bleeding (2011) (0)
Not For Sale, Not Even For Rent: Just Say No. Thoughts About the American College of Rheumatology Adopting a Code of Ethics (2008) (0)
Brand-name versus generic. Authors' reply (2007) (0)
Incorrect Sentence Wording. (2017) (0)
Book ReviewHuman Sickness and Health: A biocultural view (1979) (0)
Academic Detailing: Putting Pharmacoepidemiology into Practice (2014) (0)
Medical Education Educating Trainees about the Cost of Medications (2006) (0)
The quality of pharmaceutical care among institutionalised elderly (2007) (0)
THE RELATIVE BENEFIT OF FULL PRESCRIPTION COVERAGE VERSUS USUAL PRESCRIPTION COVERAGE IN PATIENTS UNDERGOING PCI: AN ANALYSIS FROM THE MI FREEE TRIAL (2012) (0)
Discovery and Development of Pregabalin (Lyrica) (2021) (0)
Biotechnology products and university-based science. Authors' reply (2005) (0)
155 ppGerry Stimson and Barbara Webb, Going to See the Doctor: The Consultation Process in General Practice, Routledge and Kegan Paul, Durham (1975). (1978) (0)
Comparing analytic strategies using propensity and disease risk scores: The example of nonsteroidal antiinflammatory drugs (NSAID) and short-term mortality in the elderly (2003) (0)
Brand-Name Versus Generic: The Authors Respond (2007) (0)
The Case of Coronary Artery Stents (0)
Nonsteroidal Anti-inflammatory Drug\p=m-\Associated Azotemia (2016) (0)
As older patients move through time, often from physician to physician, they are at increasing risk of accumulating layer upon layer of drug therapy, as a reef accumulates layer upon layer of coral. (2016) (0)
Abstract 13548: Full Prescription Coverage versus Usual Prescription Coverage after Coronary Artery Bypass Graft Surgery for Recent Myocardial Infarction: Analysis from the MI FREEE Randomized Trial (2012) (0)
Abstract 1424: The Impact of Statins on the Incidence of Atrial Fibrillation in Patients With Coronary Artery Disease (2009) (0)
Perspective The NEW ENGL A ND JOUR NA L of MEDICI NE (2012) (0)
Transparency on Prescription Drug Research Expenditures (2019) (0)
Educating Trainees about the Cost of Medications. (2006) (0)
PSY66 Use of Medicaid Analytic Extract for Evaluation of Drug Use and Health Services Utilization in Patients With Hemophilia (2012) (0)
Barron's in-depth guide to the Ivy League schools : the guide which gives an inside view no college catalog can give and tells it "like it is" (1971) (0)
Book ReviewAlcohol and Old Age Ailments of Aging: From symptom to treatment (1981) (0)
Gerios: Recommending DrugsandDosing forElderly Patients (2002) (0)
Medication adherence and healthcare disparities: impact of statin co-payment reduction. (2015) (0)
exploring Innovative Methods to Identify Patient Subgroup Treatment Response : 726. (2015) (0)
speculations Drug innovation and public policy : some (2002) (0)
Overcoming Decisional Gaps in High-Risk Prescribing by Junior Physicians Using Simulation-Based Training: Protocol for a Randomized Controlled Trial (2022) (0)
Book ReviewThe Core of Geriatric Medicine: A guide for students and practitoners Geriatric Neurology: Selected topics A New Look at Senility: Its causes, diagnosis, treatment, and management The Law of Deviation of Homeostasis and Diseases of Aging (1982) (0)
Book ReviewFundamentals of Geriatric Medicine (1984) (0)
Clinical and economic consequences of formulary restrictions for three leading proton pump inhibitors (2005) (0)
Changing prescribing patterns: How can theories of change help? (2001) (0)
Inconsistency in the Editorial Process in Archives of Internal Medicine?—Reply (2005) (0)
Hydroxyethyl Starch-Induced Postoperative Bleeding in Cardiac Surgery Patients (2004) (0)

This paper list is powered by the following services:

Other Resources About Jerry Avorn

en.wikipedia.org

What Schools Are Affiliated With Jerry Avorn?

Jerry Avorn is affiliated with the following schools:

Jerry Avorn's Academic­Influence.com Rankings